Article
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.
Blood cancer journal - 17 Feb 2023
Che Yuxuan, Liu Yang, Yao Yixin, Hill Holly A, Li Yijing, Cai Qingsong, Yan Fangfang, Jain Preetesh, Wang Wei, Rui Lixin, Wang Michael
Abstract excerpt
Constant challenges for the treatment of mantle cell lymphoma (MCL) remain to be recurrent relapses and therapy resistance, especially in patients harboring somatic mutations in the tumor suppressors ATM and TP53, which are accumulated as therapy resistance emerges and the disease progresses, consistent with our OncoPrint results that ATM and TP53 alterations were most frequent in relapsed/refractory (R/R) MCL....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.